EXHIBIT 99.2
Report of Voting Results
In accordance with Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, we advise of the results of the voting on the matters submitted to the annual general and special meeting (“Meeting”) of the shareholders of Eupraxia Pharmaceuticals Inc. (“Company”) held on June 6, 2024.
The matters voted on at the Meeting and the results of the voting were as follows:
Item 1: Number of Directors
On a vote by ballot, the shareholders approved setting the number of directors at six.
| Votes For | % For | Votes Against | % Against |
| 13,172,020 | 99.999 | 100 | 0.001 |
Item 2: Election of Directors
On a vote by ballot, the following nominees were elected as directors to serve until the next annual meeting of shareholders of the Company or until his or her successor is duly elected or appointed.
| Director Nominee | Votes For | % For | Votes Withheld | % Withheld |
| James A. Helliwell | 12,566,498 | 99.880 | 15,100 | 0.120 |
| Simon Pimstone | 11,691,796 | 92.928 | 889,802 | 7.072 |
| Richard M. Glickman | 12,521,398 | 99.522 | 60,200 | 0.478 |
| Paul Geyer | 12,565,748 | 99.874 | 15,850 | 0.126 |
| John Montalbano | 12,566,498 | 99.880 | 15,100 | 0.120 |
| Michael Wilmink | 12,566,498 | 99.880 | 15,100 | 0.120 |
Item 3: Appointment of Auditors
On a vote by ballot, the shareholders appointed KPMG LLP as auditor of the Company for the ensuing year and authorized the directors to set the auditor’s pay.
| Votes For | % For | Votes Withheld | % Withheld |
| 13,170,620 | 99.989 | 1,500 | 0.011 |
Item 4: Approval of Unallocated Entitlements under the Stock Option Plan
On a vote by ballot, disinterested shareholders passed a resolution approving unallocated entitlements under the Company’s amended and restated stock option plan.
| Votes For | % For | Votes Against | % Against |
| 10,493,129 | 92.175 | 890,802 | 7.825 |
Item 5: Amendment to Company Articles
On a vote by ballot, a special majority of shareholders passed a resolution amending the Articles of the Company to provide that the Company may, by a resolution of the directors, consolidate or subdivide all or any of the Company’s unissued, or fully paid issued, shares.
| Votes For | % For | Votes Against | % Against |
| 11,628,774 | 92.427 | 952,823 | 7.573 |
Yours truly,
Eupraxia Pharmaceuticals Inc.
(signed) “James A. Helliwell”___
Chief Executive Officer
